R
Rubén Alvarez-Sánchez
Researcher at Hoffmann-La Roche
Publications - 26
Citations - 788
Rubén Alvarez-Sánchez is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: In vivo & Thioamide. The author has an hindex of 14, co-authored 26 publications receiving 670 citations.
Papers
More filters
Journal ArticleDOI
Glutathione conjugates of 4-hydroxy-2(E)-nonenal as biomarkers of hepatic oxidative stress-induced lipid peroxidation in rats
Wolfgang Völkel,Rubén Alvarez-Sánchez,Idelette Weick,Angela Mally,Wolfgang Dekant,Axel Pähler +5 more
TL;DR: The direct measurement of the stable GSH conjugation product of cellular HNE in rat primary hepatocytes or its secondary metabolites may represent a reliable biomarker of oxidative stress-induced lipid peroxidation in rat liver in vivo.
Journal ArticleDOI
Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.
TL;DR: The data suggest that all drugs undergo bioactivation processes via a common metabolic activation on the TZD ring, yielding disulfide type GSH conjugates as evidenced by the loss of labeled positions in the TzD moiety.
Journal ArticleDOI
Studies of chemical selectivity of hapten, reactivity, and skin sensitization potency. 3. Synthesis and studies on the reactivity toward model nucleophiles of the 13C-labeled skin sensitizers, 5-chloro-2-methylisothiazol-3-one (MCI) and 2-methylisothiazol-3-one (MI).
TL;DR: Although both MCI and MI can react with thiol nucleophiles, only MCI is capable of significantly reacting with aminoucleophiles of the Lys or His type.
Journal ArticleDOI
Incretin-like effects of small molecule trace amine-associated receptor 1 agonists
Susanne Raab,Haiyan Wang,Sabine Uhles,Nadine Cole,Rubén Alvarez-Sánchez,Basil Künnecke,Christoph Ullmer,Hugues Matile,Marc Bedoucha,Roger David Norcross,Nickki Ottaway-Parker,Diego Perez-Tilve,Karin Conde Knape,Matthias H. Tschöp,Marius C. Hoener,Sabine Sewing +15 more
TL;DR: TAAR1 qualifies as a novel and promising target for the treatment of type 2 diabetes and obesity because it is a novel integrator of metabolic control, which acts on gastrointestinal and pancreatic islet hormone secretion.
Journal ArticleDOI
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
Simone Schadt,Silke Simon,Stefan Kustermann,Franziska Boess,Claudia McGinnis,Andreas Brink,R. Lieven,Stephen Fowler,Kuresh Youdim,Mohammed Ullah,Michaela Marschmann,C. Zihlmann,Y.M. Siegrist,Anne-Christine Cascais,E. Di Lenarda,E. Durr,N. Schaub,X. Ang,Volkmar Starke,Thomas Singer,Rubén Alvarez-Sánchez,Adrian Roth,Franz Schuler,Christoph Funk +23 more
TL;DR: This test system may be applied in a prospective manner to reduce the risk of idiosyncratic DILI of drug candidates.